Recent Quotes (30 days)

You have no recent quotes
chg | %

Hikma Pharmaceuticals Plc  

(Public, LON:HIK)   Watch this stock  
Find more results forHIK
1,161.84
+34.84 (3.09%)
Sep 25 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,123.00 - 1,175.00
52 week 1,101.00 - 2,346.00
Open 1,131.00
Vol / Avg. 418,069.00/849,416.00
Mkt cap 2,813.92M*
P/E 22.70
Div/yield 8.50*
EPS 0.51*
Shares 240.65M
Beta     -
Inst. own     -
*GBP
Nov 21, 2017
Hikma Pharmaceuticals PLC at JPMorgan "Best of British" Conference Add to calendar
Nov 15, 2017
Hikma Pharmaceuticals PLC at Jefferies Global Healthcare Conference Add to calendar
Nov 13, 2017
Hikma Pharmaceuticals PLC at Goldman Sachs CEEMEA 1x1 Conference Add to calendar
Nov 9, 2017
Hikma Pharmaceuticals PLC Interim Management Statement Release - 8:00am GMT - Add to calendar
Sep 13, 2017
Hikma Pharmaceuticals PLC at Bank of America Merrill Lynch Health Care Conference
Sep 12, 2017
Hikma Pharmaceuticals PLC at Morgan Stanley Healthcare Conference
Aug 17, 2017
Half Year 2017 Hikma Pharmaceuticals PLC Earnings Call - Webcast
Aug 17, 2017
Half Year 2017 Hikma Pharmaceuticals PLC Earnings Release
  

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 7.82% 8.10%
Operating margin 14.30% 13.85%
EBITD margin - 27.23%
Return on average assets 3.19% 4.54%
Return on average equity 5.69% 8.30%
Employees 8,339 -
CDP Score - B

Address

1 New Burlington Place
LONDON, W1S 2HR
United Kingdom - Map
+44-20-73992760 (Phone)
+44-20-73992761 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Officers and directors

Said Darwazah Chairman of the Board, Chief Executive
Age: 59
Mazen Samih Talib Darwazah Executive Vice Chairman of the Board, President and Chief Executive Officer of MENA and Emerging Markets
Age: 58
Khalid Nabilsi Chief Financial Officer
Brian Hoffman President, West-Ward Pharmaceuticals
Michael Raya Chief Executive Officer, West-Ward Pharmaceuticals
Majda Labadi Corporate Vice President - Human Resources and Head of Operations, MENA
Riad Mishlawi EU Vice President and Global Head - Injectables
Susan Ringdal Vice President - Corporate Strategy and Investor Relations
Hussein Arkhagha General Counsel
Bassam Wael Rushdi Kanaan Chief Strategy and Corporate Development Officer
Age: 51